Axing Restasis Patents Would Stifle Innovation, PhRMA Warns
The Pharmaceutical Research and Manufacturers of America on Wednesday warned the Federal Circuit that allowing a district court to invalidate four patents tied to the dry-eye medication Restasis will block innovation...To view the full article, register now.
Already a subscriber? Click here to view full article